Thermally Oxidized Nanodiamond: An Effective Sorbent for Separation of Methotrexate from Aqueous Media: Synthesis, Characterization, In Vivo and In Vitro Biocompatibility Study
- 6 Downloads
In the present study the effect of nanodiamond (ND) on the adsorption capacity of Drug has been investigated. Thermal oxidation nanodiamond (OND) was used as adsorbents for Methotrexate adsorption. The surface properties of NDs were studied by Fourier transform infrared spectroscopy and zeta potential. It was determined that thermal oxidation changed the surface properties of ND, including increase the amount of carboxylic acid groups and decreasing the zeta potential of ND by increasing the thermal oxidation time. The adsorption experiments showed that untreated ND (UND) has large adsorption capacity and fast adsorption kinetic for methotrexate (MTX). These results suggest that the adsorption behavior of UND with the MTX follows not only the charge but also the chemical interaction. Due to form the strong hydrogen bond between the carboxyl groups of MTX and the oxygen containing groups on the surface of NDs, Kinetic studies showed that the kinetic data are well fitted with the pseudo- second-order model for most of the adsorbents. MTT assay, Hemolysis assay and acute toxicity were used for determining biocompatibility of the adsorbents; MTT assay showed no significant toxicity up to near 300 µg/mL, OND showed neglectable hemolysis and acute toxicity result demonstrated OND was nontoxic.
KeywordsNanodiamond Drug adsorption Biocompatibility Methotrexate
This study was supported financially by Zanjan University of medical science (Grant No. A-12-430-33), and Sharif University of Technology, Iran.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.H. Hedegaard, M. Warner, A.M. Miniño, Drug overdose deaths in the United States, 1999–2015: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics (2017)Google Scholar
- 3.R.C. Dart, L.R. Goldfrank, B.L. Erstad, D.T. Huang, K.H. Todd, J. Weitz et al., Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann. Emerg. Med. 54(3), 386–394 (2017)Google Scholar
- 4.S. Glund, V. Moschetti, S. Norris, J. Stangier, M. Schmohl, J. van Ryn et al., A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb. Haemost. 114(05), 943–951 (2015)Google Scholar
- 13.D.G. Ilyushin, I.V. Smirnov, A.A. Belogurov, I.A. Dyachenko, T.I. Zharmukhamedova, T.I. Novozhilova et al., Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. Proc. Natl. Acad. Sci. 110(4):1243–1248 (2013)CrossRefGoogle Scholar
- 32.M. Zamani, E. Naderi, M. Aghajanzadeh, M. Naseri, A. Sharafi, H. Danafar, Co1—XZnxFe2O4 based nanocarriers for dual-targeted anticancer drug delivery: synthesis, characterization and in vivo and in vitro biocompatibility study. J. Mol. Liquids 274, 60–67 (2018)Google Scholar
- 33.O.O. Guideline, 425: acute oral toxicity—up-and-down procedure. OECD Guidel Test. Chem. 2, 6–12 (2001)Google Scholar